Agno Pharmaceuticals

Agno Pharmaceuticals is a premier, global, end-to-end Contract Development and Manufacturing Organization (CDMO) headquartered in Bethlehem, Pennsylvania. Established in 2004, the company provides comprehensive cGMP manufacturing solutions, specializing in the development and production of regulatory starting materials (RSMs), chemical intermediates, and active pharmaceutical ingredients (APIs), including highly potent and sterile APIs. Beyond API development, Agno excels in complex drug product formulation, including sterile injectables, suspensions, emulsions, and long-acting implants. The company operates facilities in the United States and China, leveraging a synergistic approach that combines North American pharmaceutical technologies with global manufacturing capabilities. In December 2023, Agno acquired Particle Sciences, further enhancing its expertise in complex drug product formulation and drug-eluting devices.